sln (2) presentation current
TRANSCRIPT
![Page 1: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/1.jpg)
Effect of formulation variableson solid lipid nanoparticles
Presented byMs. Amruta Sunil Ner
Guided byDr. Mrs. A. R. Madgulkar
AISSMS COLLEGE OF PHARMACY, PUNE-01
1
![Page 2: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/2.jpg)
Contents:Introduction to SLNsMethods of preparationFormulation variables which affect SLNs Properties affected by formulation variablesStabilityApplications
2
![Page 3: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/3.jpg)
Introduction:Definition:Nanoparticles: nanoparticles are solid colloidal
particles which ranging in size from 10 to 1000nm (1 μm). They consist of macromolecular materials such as adjuvant in vaccines or drug carriers in which the active principle (the drug or biologically active material) is dissolved, entrapped or encapsulated or to which active principle is adsorbed or attached.
Solid lipid nanoparticles: solid lipid nanoparticles are colloidal carriers which consist of spherical solid lipid particles in nanometer range. They are made up of lipid(s), emulsifier(s) and water.
3
![Page 4: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/4.jpg)
Advantages of SLN:Controlled drug releaseTargeting of drugIncreased drug stabilityHigh drug loading capacityLess toxicAvoidance of organic solventsProtection of drugLarge scale productionWide spectrum of application.
4
![Page 5: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/5.jpg)
Disadvantages:Particle growth.
Unpredictable gelation tendency.
Unexpected dynamics of polymorphic transitions.
Inherent low incorporation rate due to the
crystalline structure of the solid lipid.
5
![Page 6: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/6.jpg)
Components of solid lipid nanoparticles: Lipids: Selection of lipid is based on solubility of
drug in various Lipids. There are various lipid are used like Stearic acid, Glyceryl monostearate, Compritol ATO888(Glyceryl behenate),Precirol ATO5(Glyceryl palmitostearate),Gelucire, Emulcire.
Surfactants: Various lipophilic and hydrophilic surfactants are used. lipophilic surfactants are used to enhance drug solubility in lipid. Hydrophilic surfactants used to stabilize the formulation.Lipophilic surfactants: Span 60,Sodium cholate, Soya lecithin.Hydrophilic surfactants: Tween 80,Poloxamer 188.
6
![Page 7: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/7.jpg)
Types of solid lipid nanoparticles: The type of SLNs depends:The chemical nature of the active ingredient and
lipid, The solubility of actives in the melted lipid,Nature and concentration of surfactants, Type of production (hot vs. cold HPH), and the
production temperature.Fig. structural models for drug loading profiles in
SLNs
7
![Page 8: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/8.jpg)
Drug release: Types:
• Control release
• Burst release
• Enzyme dependent release
8
![Page 9: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/9.jpg)
Controlled release:
• This type of release showed with a uniform drug profile throughout the lipid shell or an enriched ‘core’.
9
![Page 10: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/10.jpg)
Burst release:
Affected by 2 factors:
• Processing temperature
• Concentration of surfactant
10
![Page 11: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/11.jpg)
Enzyme release:
• Enzymatic release of drug from SLN takes place by lipase/ colipase complex.
• Components accelerating degradation-Cholic acid sodium saltTween 80
• Components preventing degradation-Waxes (cetyl palmitate)Poloxamer 407
11
![Page 12: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/12.jpg)
Methods of SLN preparation: A. Mechanical methods: High shear homogenizationHigh pressure homogenizationUltrasonication
B. Chemical methods:Solvent evaporationMicroemulsions
12
![Page 13: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/13.jpg)
A. High pressure homogenization:Principle: It is based on principles of fluid
mechanics to produce extremely high fluid pressures, and, thus energy dissipation rates in the form of high shear stresses and cavitation forces that act to reduce the size of dispersed phase in emulsions.
• Two types:1.Hot pressure homogenization2.Cold pressure homogenization
13
![Page 14: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/14.jpg)
14
![Page 15: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/15.jpg)
B. Probe sonication method:
15
![Page 16: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/16.jpg)
C) Micro-emulsion dilution method:Preparation of micro-emulsionDilution of micro-emulsion into near freezing
temperature at ratios of 1:25-1:50 to cold water to form lipid nanoparticles.
D) Solvent evaporation method:Lipid with drug mixed with water immiscible
solvent and then emulsified with water.Emulsion is then subject to reduced pressure
to evaporate solvent and precipitate lipid particles as aqueous dispersion.
16
![Page 17: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/17.jpg)
Methods of Preparation Strengths weaknessesHot Pressure homogenization Scalable
Mature technology Continuous operation Commercially
demonstrated
Extremely energy intensive process
Polydisperse distributions Biomolecule damage Not used for thermolabile
drugCold pressure homogenization Mature technology
Continuous operation Commercially
demonstrated Mainly used for the
thermolabile and hydrophilic drugs
Extremely energy intensive process
Polydisperse distributions Biomolecule damage
Ultrasonication Reduced shear stress Metal contamination potential
Energy intensive process Polydisperse distributions
Microemulsion dilution Low mechanical energy input
Theoretical stability
Extremely sensitive to change
Labor intensive formulation work
Low nanoparticles concentrations
Solvent evaporation No dilution solidification Residual organic solvent
17
![Page 18: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/18.jpg)
Formulation variables which affect SLN:
Lipids
Surfactants
Processing parameters (stirring time, stirring rate,
rate of cooling,
temperature)
Drug
Spray drying
Lyophilization
sterilization18
![Page 19: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/19.jpg)
Factors which are affected by formulation variables:Particle size
Polydispersity index (P.I.)
Zeta potential
% entrapment efficiency
drug release
19
![Page 20: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/20.jpg)
Lipids:Properties of lipids which affect SLNs:
Melting point of lipid
Concentration of lipid
Composition of lipids
Combination of lipids
Lipid crystallinity
Chemistry of lipids
20
![Page 21: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/21.jpg)
21
Effect of lipid melting point (M.P.) on processing parameter
(In homogenization method)
lipid Stirring time Stirring rate Optimum cooling condition
Witepsol W 35(M.P. 450c)
8 minute 20,000 rpm 10 minute(in room temperature)
Dynasan 116(M.P. 640c)
10 minute 25,000 rpm 5 minute(in cool water)
![Page 22: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/22.jpg)
Lipid crystalline state:Crystallization is a balance between attractive
intermolecular forces and entropic factors. SLNs exhibits in various crystalline structure:
1. α-form.2. β′-form.3. β -form.4. Super cooled melt
22
![Page 23: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/23.jpg)
Lipid crystallization depends on:• Rate of cooling• type of hydrophobic group in surfactant.
Lipid crystallization mainly affects:• Drug incorporation • Drug release characteristics.
23
![Page 24: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/24.jpg)
Effect of lipid matrix on drug release:
Different lipids give different release kinetics.
Example:
Release rate decreases in following order-
Triglyceryl stearate > triglyceryl palmitate >
myristin.
• Effect of waxes on drug release:
• Example – cetyl palmitate
24
![Page 25: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/25.jpg)
Effect of surfactants:Effects are due to:
• Temperature • Surfactant mixture/ cosurfactants, surfactant to cosurfactant molar ratio• HLB number• Surfactant number (CPP)• Amount of emulsifier, surfactant to lipid
molar ratio• Molecular weight and speed of redistribution• Varying rates of adsorption onto interface
25
![Page 26: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/26.jpg)
Effect of temperature: Ionic surfactants: becomes more hydrophilic.Non ionic surfactants: becomes more hydrophobic.
Effect of surfactant mixture on particle size:
26
surfactant Particle size before freezing
Particle size after freezing
Tween 80(100%) 487.7 1459.7
Egg PC(100%) 397.1 440.3
Tween 80: Egg PC (46:56)
227.2 329.5
![Page 27: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/27.jpg)
Effect of cosurfactant selection on lipid nanoparticle characteristics:
27
cosurfactant Particle size (nm)
Polydispersity index
Sodium taurocholate
99 0.30
Sodium glycocholate
110 0.01
cholesterol 620 0.01
![Page 28: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/28.jpg)
Effect of concentration of surfactant on:
Particle size
% entrapment efficiency
28
![Page 29: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/29.jpg)
Steric stabilizers:Ex. Poloxamer 407 PEG poloxamine 908Effect due ethylene oxide/ propylene oxide
copolymers
29
Example No. of ethylene oxide chains
Molecular weight
Adsorbed layer thickness
Poloxamer 407 98 11500 12nm
Tween 80 20 1840 2nm
![Page 30: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/30.jpg)
• Effect of type of surfactants on drug release:
• Effect on enzymatic release:• Enzymatic release of SLN takes place by lipase/
colipase complex
• Components accelerating degradation- Cholic acid sodium salt(bile salt) Tween 80(ethylene oxide propylene oxide copolymer)
• Components preventing degradation- Poloxamer 407(ethylene oxide propylene oxide
copolymer)
30
![Page 31: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/31.jpg)
Drug: Effect of drug nature:
• Lipophilic drug
• Hydrophilic drug
31
![Page 32: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/32.jpg)
Processing parameters:• Homogenization cycles
• Stirring time
• Stirring rate
• Rate of cooling
• Processing temperature
32
![Page 33: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/33.jpg)
Effect of processing temperature on:• Particle size• Degradation• Drug distribution• Increase of processing temperature causes
burst release to take place.1. burst release:Fig. drug enriched shell model
33
![Page 34: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/34.jpg)
Lyophilization:Following points considered:• Effect of drug• Effect of lipid content• Selection of cryoprotector• Concentration of cryoprotector• Time of addition of cryoprotector Effect of rate of cooling:• Rapid cooling- gives small crystals• Slow cooling- gives larger crystals
34
![Page 35: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/35.jpg)
Spray drying:• During spray drying particle aggregation is
the main problem.• Points to be considered to avoid particle
aggregation:
Selection of lipids
Concentration of lipids
Addition of carbohydrates
Use of ethanol-water mixture
35
![Page 36: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/36.jpg)
Sterilization:Autoclaving: Effect of surfactant- Poloxamer 188 Lecithin
Sterile filtration: use it if particle size is less than 200nm.
Gamma irradiation
36
![Page 37: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/37.jpg)
Stability: Properties considered:• Particle size distribution (increase particle
size, gelation)• Lipid crystallization state
Stability studies performed for effect of: • Light • Temperature• Packaging material
37
![Page 38: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/38.jpg)
• Example: poloxamer 188 stabilized compritol SLN:
• Stability achieved by: Temperature- 8oC Light- dark Container-siliconized vials.
38
![Page 39: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/39.jpg)
Effect of lipids and surfactants on SLNs stability:
Speed of lipid crystallinity and surfactant properties affect speed of degradation of SLNs.
Example:
degradation velocity can be modulated by changing surfactant ratio:
Degradation velocity: Cholic acid > Lipoid E 80 > Tween 80 >
Poloxamer 407. 39
Lipid Surfactant
1. Dynasan 116(Tripalmitin)
M.P.(640c)
1. Poloxamer 407
2. Dynasan 114(Trimyristin) M.P.(560c)
2. Sodium cholate
![Page 40: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/40.jpg)
Applications:SLN can be given by various routs as follows:
• Oral route
• Intravenous route
• Transdermal route
• Occular route.
40
![Page 41: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/41.jpg)
References:1. Muller RH, Mäder K. Gohla S. Solid lipid
nanoparticles (SLN) for controlled drug delivery - A review of the state of art. Eur. J. Pharm. Biopharm 2000;50: 161-177.
2. Khar RK, Vyas SP. Targeted and Controlled Drug Delivery. CBS Publishers & Distributors.1st Edi,Vol.II,2002, 331-383.
3. Manjunath K, Reddy JS, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find. Exp. Clin. Pharmacol. 2005; 27:127-144.
4. Mehnert W, Mäder K. Solid lipid nanoparticles - Production, characterization and applications. Adv. Drug Deliv. Rev 2001; 47:165-196.
41
![Page 42: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/42.jpg)
References:5) Gupta R.B., Kompella U.B., Nanoparticle technology for
drug delivery, Taylor and Francis group,Vol.159,pg no.1-45.
6) Tassu D., Deelers M., Pathak Y., Nanoparticulates drug delivery systems., Taylor and Francis group,Vol.166,pg no.89-98.
7) ) Freitas C, Muller RH, “Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle dispersions”, Int. J. Pharm., 168, 1998, 221-228.
8) Olbrich C, Muller RH, “Enzymatic degradation of SLN- effect of surfactant and surfactant mixtures”, Int. J. Pharm., 180, 1999, 31-39.
9) Attama AA, Christel C, Muller- Goymann, “Effect of beeswax modification on the lipid matrix and solid lipid nanoparticle crystallinity”, Colloids and Surfaces A: Physicochem. Eng. Aspects, 315, 2008, 189- 195.
42
![Page 43: Sln (2) Presentation Current](https://reader033.vdocuments.mx/reader033/viewer/2022051108/546b2d40b4af9fca128b4f2b/html5/thumbnails/43.jpg)
Thank you…